Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bomedemstat (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Adverse reactions; Registrational
  • Acronyms MK-3543-017
  • Sponsors Imago BioSciences; Merck Sharp & Dohme

    • Most Recent Events

    • 27 May 2024 Status changed from not yet recruiting to recruiting.
    • 02 Apr 2024 Status changed from planning to not yet recruiting.
    • 12 Dec 2022 According to an Imago BioSciences media release, the company has recently conducted an End-of-Phase 2 meeting with the FDA and aligned on a strategy for the bomedemstat Phase 3 registrational program in ET.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top